X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6007) 6007
Book Review (1072) 1072
Publication (503) 503
Magazine Article (22) 22
Book Chapter (11) 11
Conference Proceeding (9) 9
Dissertation (4) 4
Data Set (2) 2
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5495) 5495
humans (4692) 4692
male (2869) 2869
female (2406) 2406
pyrazoles - therapeutic use (2321) 2321
pyrazoles - adverse effects (2267) 2267
animals (1795) 1795
middle aged (1650) 1650
pyrazoles - pharmacology (1595) 1595
celecoxib (1569) 1569
aged (1514) 1514
pyrazoles - administration & dosage (1346) 1346
adult (1308) 1308
pharmacology & pharmacy (1038) 1038
treatment outcome (923) 923
sulfonamides - adverse effects (875) 875
oncology (768) 768
rats (747) 747
sulfonamides - therapeutic use (747) 747
pyrazoles (727) 727
abridged index medicus (706) 706
dose-response relationship, drug (601) 601
mice (601) 601
anti-inflammatory agents, non-steroidal - adverse effects (584) 584
aged, 80 and over (556) 556
administration, oral (551) 551
hematology (522) 522
risk factors (490) 490
care and treatment (473) 473
drug therapy (470) 470
analysis (465) 465
pyridones - adverse effects (452) 452
medicine, general & internal (450) 450
nonsteroidal antiinflammatory drugs (438) 438
cyclooxygenase inhibitors - adverse effects (435) 435
double-blind method (434) 434
pyridones - therapeutic use (408) 408
anticoagulants - adverse effects (406) 406
research (391) 391
dabigatran (385) 385
sulfonamides - pharmacology (381) 381
rivaroxaban (378) 378
medicine & public health (376) 376
cancer (375) 375
time factors (373) 373
pyrazoles - pharmacokinetics (372) 372
sulfonamides - administration & dosage (369) 369
anti-inflammatory agents, non-steroidal - therapeutic use (363) 363
piperidines - pharmacology (357) 357
safety (356) 356
cox-2 inhibitors (350) 350
anticoagulants (344) 344
anticoagulants - therapeutic use (342) 342
cyclooxygenase inhibitors - therapeutic use (336) 336
protein kinase inhibitors - therapeutic use (333) 333
cardiac & cardiovascular systems (326) 326
pyrimidines - therapeutic use (314) 314
adolescent (313) 313
risk (307) 307
warfarin (307) 307
clinical trials (306) 306
double-blind (306) 306
antineoplastic agents - therapeutic use (305) 305
pyridones - administration & dosage (304) 304
hemorrhage - chemically induced (302) 302
apixaban (300) 300
efficacy (298) 298
rheumatoid-arthritis (296) 296
neurosciences (295) 295
pyridines - therapeutic use (293) 293
expression (290) 290
pyrazoles - chemistry (289) 289
clinical trials as topic (286) 286
article (283) 283
prevention (280) 280
randomized controlled trials as topic (279) 279
lactones - adverse effects (276) 276
receptor, cannabinoid, cb1 - antagonists & inhibitors (273) 273
therapy (273) 273
drug administration schedule (269) 269
atrial fibrillation - drug therapy (265) 265
cyclooxygenase 2 (264) 264
health aspects (263) 263
young adult (262) 262
piperidines - therapeutic use (260) 260
antineoplastic agents - adverse effects (259) 259
cyclooxygenase 2 inhibitors (251) 251
protein kinase inhibitors - adverse effects (250) 250
stroke - prevention & control (250) 250
anticoagulants - administration & dosage (249) 249
pyrimidines - adverse effects (249) 249
pyridines - adverse effects (248) 248
toxicology (248) 248
atrial fibrillation (245) 245
chemotherapy (245) 245
disease models, animal (245) 245
rats, sprague-dawley (245) 245
drug interactions (243) 243
patients (238) 238
lung neoplasms - drug therapy (235) 235
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5559) 5559
German (163) 163
French (76) 76
Spanish (60) 60
Italian (35) 35
Japanese (33) 33
Chinese (17) 17
Russian (16) 16
Dutch (11) 11
Norwegian (11) 11
Polish (11) 11
Danish (7) 7
Hungarian (7) 7
Swedish (6) 6
Czech (5) 5
Portuguese (5) 5
Croatian (3) 3
Romanian (3) 3
Finnish (2) 2
Serbian (2) 2
Slovak (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Nuclear Cardiology, ISSN 1071-3581, 06/2017, Volume 24, Issue 3, pp. 1071 - 1074
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12350-016-0484-5 
TRIAL | ADENOSINE | CARDIAC & CARDIOVASCULAR SYSTEMS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | AGONIST | Purines | Vasodilator Agents | Exercise Test | Pyrazoles | Aminophylline | Caffeine | Myocardial Perfusion Imaging | Complications and side effects | Cardiology | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
Toxicology Letters, ISSN 0378-4274, 2004, Volume 146, Issue 2, pp. 121 - 127
The purpose of the present study was to investigate possible reproductive adverse effects of fipronil (Frontline® TopSpot™) in female Wistar rats. The... 
Estrous cycle | Wistar rat | Reproductive toxicology | Fipronil | Estradiol - blood | Pregnancy | Reproduction - drug effects | Animals | Rats, Wistar | Pyrazoles - toxicity | Rats | Female | Progesterone - blood | Estrus - drug effects | Insecticides - toxicity | Pregnancy Outcome | fipronil | Index Medicus
Journal Article